Health Equity and Innovation Are at Risk for All of Us

The rapid development of COVID-19 vaccines illustrates what’s possible when federal policy fosters innovation with a real public-private partnership, especially for the health challenges facing America’s more than 54 million older adults. Yet, a number of drug-pricing policy proposals now jeopardize this very model, threatening to limit access to prescription drugs, compromise health equity and slow progress on urgently needed new treatments for age-related chronic conditions.

Rather than build on the lessons of COVID-19, Washington seems to be trying to rewrite them — and our aging population can ill afford the unintended consequences. If we are worried about the fiscal sustainability of Medicare, let’s be honest about the problem: a program created nearly 60 years ago when we had neither a fraction of the elderly we have today nor the medicines, therapies, treatments, diagnostics and digital health now available. Demand is simply outpacing the ability of Medicare to cope. Pretending that reducing drug prices is the answer is nothing less than public policy malpractice.

Instead, finding new solutions for healthy aging is vitally important as we enter an era defined by longevity — when most health needs arise — and by a society with more old than young. Paying for and investing in innovation, including biomedical miracles, is the only way to mitigate the fast-growing health and economic toll of complex, chronic conditions of aging.

Currently, more than 80 percent of Medicare beneficiaries are managing at least one chronic condition, such as Alzheimer’s disease, heart failure, osteoporosis and diseases that impair vision. Additionally, there are a number of seniors still managing HIV who depend on effective and innovative treatments to manage their health. Current proposals would have an adverse effect on future innovations in HIV that are critical for disease management and our efforts to end the HIV epidemic. Health policy must stimulate innovation to meet this need while improving healthcare equity and addressing access challenges.

But what’s on the table just doesn’t work. Congress is currently considering a number of proposals that would give the government unprecedented power to negotiate the prices of certain prescription drugs. But a majority of the seniors who actually rely on the Medicare Part D prescription drug program have said they are concerned that these proposals could limit their ability to choose and access the medications they need to manage chronic diseases.

Price-setting proposals would also undercut new innovations to better control and prevent these diseases, reduce long-term costs and enable healthier aging. Even in a limited form, these proposals could remove companies’ incentive to invest in continued research and development efforts on behalf of patients. The Congressional Budget Office estimates that pricing reforms — with drug negotiation elements similar to H.R. 3 — would lead to fewer new drugs, slowing innovation when we need it most.

There’s a better way, and the innovation experiences of COVID-19 offer a clear case in point. Instead of rushing ahead with misguided policies that could harm those they intend to protect, lawmakers should support solutions that will foster a hospitable and dynamic environment for innovation in biomedical research. This is especially critical as our country and communities confront the difficult health challenges that come with modern longevity and population aging. The current proposals would stifle the innovative solutions that could serve to bend the otherwise unsustainable rise in health costs — not the drugs, but hospital stays, doctor visits and other health costs, which are themselves mitigated by biomedical innovation.

In addition, Congress should support health policies that directly address socioeconomic barriers to care, improve health equity and ensure treatment access for patients of all ages and backgrounds. Capping Medicare Part D annual out-of-pocket costs at $2,000 is interesting. But it fails to do what is advertised when combined with negotiation tactics that disregard the time, resources and expenses that go into creating new and more effective treatments that will help patients, caregivers and families across the country.

The COVID-19 pandemic illustrated just how quickly the pharmaceutical industry can develop incredibly effective therapeutics and vaccines, as well as other innovation support in areas such as digital health. But we need supportive public policies, which can then become the basis to apply the equity lens, so these miracle solutions are scaled across all societies. Rather than flipping our entire system for health innovation on its head as we emerge from the pandemic, federal policymakers should strengthen the system that continues to bring life-saving cures to all Americans and address existing health disparities. Health equity and ongoing biomedical innovation are profoundly dependent on each other and must be treated as such.

Together, we can create a system that is both more innovative and more patient-centered, accessible and equitable to support healthy aging. And while doing this, we might even find ways to enable Medicare’s 21st-century sustainability rather than the certainty that current proposals will, paradoxically, lead to its unraveling.

Source: Morning Consult

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.